Life science and healthcare specialists – AMSBIO has launched a new set of dedicated webpages and content downloads detailing their extensive range of high quality GMP-compliant products and services.
News
WESTBROOK, Connecticut (USA) - The Lee Company is pleased to announce that it has acquired TTP Ventus Limited from TTP Group. Based near Cambridge, UK, TTP Ventus is an inventor and manufacturer of silent, compact micropumps and pump modules with unrivalled features, enabling cutting-edge innovation across the medical, life science, environmental, and industrial sectors. These products complement The Lee Company’s existing broad range of miniature fluid control components widely utilized across the same industries.
XenoTech specializes in providing ADME-Tox products and research services, in particular drug metabolism and pharmacokinetics (DMPK) and drug-drug interaction (DDI) studies
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired XenoTech, a provider of products for ADME-Tox in vitro models and contract research services, from Sekisui Chemical, based in Japan. XenoTech specializes in ADME, DMPK and DDI testing of potential drug candidates.
Macomics Announces the Appointment of Roche Executive, Dr Valérie Méresse Naegelen, to its Clinical Advisory Panel
Edinburgh and Cambridge, UK, 12 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr Valérie Méresse Naegelen, Global Head of Translational Sciences Oncology at the Pharma Division of Roche has joined its panel of Clinical Advisors.
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, is highlighting recent ADME-Tox research at the 13th International Meeting of the International Society for the Study of Xenobiotics (ISSX) and 24th International Symposium on Microsomes and Drug Oxidations (MDO). This conference will be held from September 11-14 at the Westin Seattle.
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes
Press release
Macomics to Present at Upcoming Conferences, Q3 2022
Edinburgh and Cambridge, UK, 1 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to confirm that it will be presenting at a number of upcoming business and scientific conferences, as detailed below.
• Dr Luca Cassetta, co-founder and VP Immunology of Macomics will be attending the 2022 ISEH Annual meeting, Edinburgh, 1-4 September
o Speaking at Q&A session on transition from academia to start up, 2 September
AMSBIO has published an interview with Professor Marius Wernig from Stanford University, Pathology Stem Cell Institute that discusses what could be the world’s first widely applicable curative treatment for Epidermolysis Bullosa (EB).
This rare genetic disease causes chronic and incredibly painful skin wounds that often lead to an aggressive form of skin cancer and eventual death.
The next wave of talent “…are looking for destination locations that align with the values and ethos of the company and often the physical structure that’s in to enable innovation is part of what attracts the best people” Tony Jones, One Nucleus.